The Fc-Mediated Effector Function Summit

June 1, 2025

The Fc-Mediated Effector Function Summit 

Type: Conference

Dates: July 30th - 31st

Location: Boston, MA

The Fc-Mediated Effector Function Summit brings together leaders in immunology, antibody engineering, and translational science to discuss the latest advancements in Fc effector function. This focused event highlights emerging data, novel assay technologies, and strategies to optimize therapeutic antibody design for improved safety and efficacy.

July 30th, 2025 | 10:00am EDT

Unlocking the Power of Fc: Guiding Antibody Development with Deep Effector Function Insights

  • Comprehensive profiling to align Fc functionality with therapeutic goals and patient outcomes.
  • Derisking development through strategies that mitigate the unpredictability of Fc-mediated functions.
  • Leveraging functional insights to inform candidate selection, engineering strategies, and regulatory submissions at every development stage for data-driven decision making.
JOIN US

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial

September 15, 2025
Authors: Rumyantsev, A., et al. (2025). Safety and immunogenicity of UB-612 heterologous booster: A pivotal Phase 3 study. eClinicalMedicine, The Lancet. Journal: The Lancet

Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies

July 23, 2025
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum 

Antibody Engineering and Therapeutics 2025

June 4, 2025
Antibody Engineering & Therapeutics 2025

The World Vaccine Congress Europe 2025

June 3, 2025
The World Vaccine Congress Europe 2025

Festival of Biologics

June 2, 2025
Festival of Biologics

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

May 31, 2025
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.

A replicating RNA vaccine confers protection against CrimeanCongo hemorrhagic fever in cynomolgus macaques

May 31, 2025
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698

The importance of broadly measuring Fc mediated effector function early in the antibody development process

May 12, 2025
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs

Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction

April 10, 2025
Authors: Osborn, G., López-Abente, J., Adams, R. et al.

Application Note│Comprehensive Profiling of Approved Anti-CD20 mAbs Using Fc Effector Function Platform

By Abigail Harris • October 8, 2024
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
More Posts →